Laurus Labs

Laurus Labs is an Indian pharma and biotech company headquartered in Visakhapatnam. Its focus areas include active pharma ingredients, finished dosage forms, synthesis and biotechnology.
Laurus Labs manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.
Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest HiPotent API capacities in India The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS, and hydroxychloroquine tablets, which are used to treat certain types of malaria.
In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.
Laurus Labs is the "Most Promising Company of the Year 2021"
As of one of the leading manufacturers in the pharmaceutical industry, LaurusLabs was named as India's "Most Promising Company of the year" by CNBC TV18 at the 'India Business Leader Awards' in March 2021.
Great Place to Work
Laurus Labs is one of the Great Place to Work. Great Place to Work Insititue certified Laurus Labs as on the great places to work. The company was GPW certified for the third consecutive year in 2020-21. 
Other Updates 
Laurus Labs acquires Richcore Life Sciences Pvt Ltd to foray into high growth Biotechnology sector. The biotech divsion of Laurus Labs will be called as Laurus Bio.